Author of

• 20156

  +

  P1.07 - Immunology and Immunotherapy (ID 693)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 24607

    +

    P1.07-044b - Pretreatment Neutrophil/Lymphocyte Ratio and the Efficacy of Nivolumab Treatment in Non–Small-Cell Lung Cancer (ID 9375)

    09:30 - 09:30  |  Author(s): T. Yoshizawa
    • Abstract
    • Slides

    Background:
    The blood neutrophil/lymphocyte ratio (NLR) before ipilimumab administration is a useful predictive biomarker in the treatment of malignant melanoma. However, few studies have evaluated whether NLR can predict and overall survival in non–small-cell lung cancer (NSCLC).
    
    Method:
    We studied 38 patients with previously treated advanced NSCLC who had received nivolumab therapy between January 2016 and May 2017 at our hospital. Patients were divided into two groups (pretreatment NLR <5 or ≥5), and patient characteristics, treatment effect, adverse events, and immunohistochemical expression of programmed death ligand 1 (PD-L1) were evaluated in both groups.
    
    Result:
    Of the 38 patients, 12 had an NLR ≥5 and 26 had an NLR <5. Regarding patient characteristics, median PD-L1 expression on immunohistochemistry was significantly higher in the NLR <5 group than in the NLR ≥5 group (38.2% vs 1.7%, respectively; p = 0.049). The objective response rate was 39.1% vs 12.5%, respectively (p = 0.17), and the disease control rate was 95.7% vs 25%, respectively (p <0.001). The disease control rate significantly differed between groups, as did progression-free survival (median progression-free survival: 132 days in the NLR <5 group vs 49 days in the NLR ≥5 group; p = 0.009).
    
    Conclusion:
    Among patients treated with nivolumab for NSCLC, disease control rate and progression-free survival were better for patients in the NLR <5 group than for those in the NLR ≥5 group. The association between pretreatment NLR and immunohistochemical PD-L1 expression warrants further study.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.